Minimizing drug exposure in the CNS while maintaining good oral absorption

ACS Medicinal Chemistry Letters

Volumn 3, Issue 12, 2012, Pages 948-950

  Bagal, Sharan K ^a   Bungay, Peter J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; IMATINIB; INDINAVIR; MULTIDRUG RESISTANCE PROTEIN; RITONAVIR;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG ABSORPTION; DRUG EXPOSURE; DRUG METABOLISM; DRUG PENETRATION; FIRST PASS EFFECT; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; RISK REDUCTION;

EID: 84871219095     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300378n     Document Type: Review

References (8)

1. Chen, C.; Hanson, E.; Watson, J. W.; Lee, J. S. P-Glycoprotein Limits the Brain Penetration of Nonsedating but not Sedating H1-Antagonists Drug Metab. Dispos. 2003, 31, 312-318
2. Callegari, E.; Malhotra, B.; Bungay, P. J.; Webster, R.; Fenner, K. S.; Kempshall, S.; LaPerle, J. L.; Michel, M. C.; Kay, G. G. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder Br. J. Clin. Pharmacol. 2011, 72, 235-246
3. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Drug Discovery 2007, 6, 881-890
4. Van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J. R.; Raevsky, O. A. Estimation of Blood-Brain Barrier Crossing of Drugs Using Molecular Size and Shape, and H-Bonding Descriptors J. Drug Targeting 1998, 6, 151-165
5. Cole, S.; Bagal, S.; El-Kattan, A.; Fenner, K.; Hay, T.; Kempshall, S.; Lunn, G.; Varma, M.; Stupple, P.; Speed, W. Full efficacy with no CNS side-effects: Unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration Xenobiotica 2012, 42, 11-27
6. Tachibana, T.; Kato, M.; Sugiyama, Y. Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km Values Pharm. Res. 2012, 29, 651-668
7. Peng, B.; Lloyd, P.; Shran, H. Clinical Pharmacokinetics of Imatinib Clin. Pharmacokinet. 2005, 44, 879-894
8. Fenner, K. S.; Troutman, M. D.; Kempshall, S.; Cook, J. A.; Ware, J. A.; Smith, D. A.; Lee, C. A. Drug-Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro-In Vivo Correlation Using Digoxin as a Probe Drug Clin. Pharm. Ther. 2009, 85, 173-181